The FDA and the Next Wave of Drug Abuse — Proactive Pharmacovigilance

In responding to the opioid crisis, the FDA needs to recognize shifting trends in the addiction landscape. Taking a systematic approach to monitoring such trends should allow the agency to intervene promptly and appropriately to protect the public from associated risks.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 379; no. 3; pp. 205 - 207
Main Authors Throckmorton, Douglas C, Gottlieb, Scott, Woodcock, Janet
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 19.07.2018
Subjects
Addictions
Amines - therapeutic use
Analgesics
Analgesics, Opioid - adverse effects
Analgesics, Opioid - therapeutic use
Cyclohexanecarboxylic Acids - therapeutic use
Disclosure
Drug abuse
Drug dosages
Drug Therapy, Combination - adverse effects
Drug use
Drug Utilization - trends
FDA approval
Gabapentin
gamma-Aminobutyric Acid - therapeutic use
Humans
Loperamide - adverse effects
Loperamide - therapeutic use
Narcotics
Opioid-Related Disorders - prevention & control
Opioid-Related Disorders - therapy
Opioids
Pain
Pharmacovigilance
Practice Patterns, Physicians' - trends
Prescription drugs
Prescription Drugs - therapeutic use
Secologanin Tryptamine Alkaloids - therapeutic use
Social networks
Substance abuse treatment
Substance-Related Disorders - prevention & control
Trends
United States
United States Food and Drug Administration
United States
United States > US
Online AccessGet full text

Cover

More Information
Summary:In responding to the opioid crisis, the FDA needs to recognize shifting trends in the addiction landscape. Taking a systematic approach to monitoring such trends should allow the agency to intervene promptly and appropriately to protect the public from associated risks.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMp1806486